他莫昔芬是乳腺癌内分泌治疗的首选药物，对雌激素受体阳性的进展期乳腺癌病人的有效率达60％，对早期乳腺癌疗效较好，可降低复发的相对危险性和死亡率。他莫昔芬与化疗联合治疗绝经后早期乳腺癌有协同作用，且可降低对侧乳腺癌和心血管疾病的发病率，并能预防绝经后病人的骨质疏松等。 Tamoxifen is the drug of choice for endocrine therapy in breast cancer, which is effective in 60% of patients with estrogen receptor-positive advanced breast cancer and has a good effect on early-stage breast cancer and can reduce the relative risk of relapse and mortality . Tamoxifen combined with chemotherapy in the treatment of early postmenopausal breast cancer have a synergistic effect, and can reduce the incidence of contralateral breast cancer and cardiovascular disease, and can prevent osteoporosis in postmenopausal patients.